DFD-29 40 mg, a Low-dose Modified Formulation of Minocycline, versus Doxycycline 40 mg in Papulopustular Rosacea: A Meta-Analysis of the Comparative Efficacy and Safety of Two Systemic Therapies.

Name: DFD-29 40 mg, a Low-dose Modified Formulation of Minocycline, versus Doxycycline 40 mg in Papulopustular Rosacea: A Meta-Analysis of the Comparative Efficacy and Safety of Two Systemic Therapies.
Creator: Helena Schell
Published: 2025-10-30T16:40:24.097Z
Keywords: Dermatology, Rosacea

Schell, Helena; Bagattoli, Vitor; Lopes, Samantha Cristiane; Beber, João Luis; Köhler Teixeira, Gabriele

doi:10.17632/4w8kh8bsjc.1

DFD-29 40 mg, a Low-dose Modified Formulation of Minocycline, versus Doxycycline 40 mg in Papulopustular Rosacea: A Meta-Analysis of the Comparative Efficacy and Safety of Two Systemic Therapies.

Published: 30 October 2025| Version 1 | DOI: 10.17632/4w8kh8bsjc.1

Contributors:

Helena Schell,

,

Description

This systematic review and meta-analysis compared DFD-29 (modified-release minocycline 40 mg) with doxycycline 40 mg in adults with papulopustular rosacea. Randomized controlled trials identified through PubMed, Embase, and Cochrane up to September 2025 were analyzed for efficacy and safety outcomes using PRISMA 2020 standards. Three trials including 593 patients were pooled. DFD-29 showed higher treatment success (IGA 0/1) and greater lesion reduction, with similar rates of adverse events.

Files

Institutions

Centro Universitario para o Desenvolvimento do Alto Vale do Itajai

DFD-29 40 mg, a Low-dose Modified Formulation of Minocycline, versus Doxycycline 40 mg in Papulopustular Rosacea: A Meta-Analysis of the Comparative Efficacy and Safety of Two Systemic Therapies.

Description

Files

Institutions

Categories

Licence